The glucagon-like peptides (GLP-1 and GLP-2) are proglucagon-derived peptides cosecreted from gut endocrine cells in response to nutrient ingestion. GLP-1 acts as an incretin to lower blood glucose via stimulation of insulin secretion from islet ␤ cells. GLP-1 also exerts actions independent of insulin secretion, including inhibition of gastric emptying and acid secretion, reduction in food ingestion and glucagon secretion, and stimulation of ␤-cell proliferation. Administration of GLP-1 lowers blood glucose and reduces food intake in human subjects with type 2 diabetes. GLP-2 promotes nutrient absorption via expansion of the mucosal epithelium by stimulation of crypt cell proliferation and inhibition of apoptosis in the small intestine. GLP-2 also reduces epithelial permeability, and decreases meal-stimulated gastric acid secretion and gastrointestinal motility. Administration of GLP-2 in the setting of experimental intestinal injury is associated with reduced epithelial damage, decreased bacterial infection, and decreased mortality or gut injury in rodents with chemically induced enteritis, vascular-ischemia reperfusion injury, and dextran sulfate-induced colitis. GLP-2 also attenuates chemotherapy-induced mucositis via inhibition of drug-induced apoptosis in the small and large bowel. GLP-2 improves intestinal adaptation and nutrient absorption in rats after major small bowel resection, and in humans with short bowel syndrome. The actions of GLP-2 are mediated by a distinct GLP-2 receptor expressed on subsets of enteric nerves and enteroendocrine cells in the stomach and small and large intestine. The beneficial actions of GLP-1 and GLP-2 in preclinical and clinical studies of diabetes and intestinal disease, respectively, has fostered interest in the potential therapeutic use of these gut peptides. Nevertheless, the actions of the glucagon-like peptides are limited in duration by enzymatic inactivation via cleavage at the N-terminal penultimate alanine by dipeptidyl peptidase IV (DP IV). Hence, inhibitors of DP IV activity, or DP IVresistant glucagon-like peptide analogues, may be alternative therapeutic approaches for treatment of human diseases.
G lucagon, a 29 amino acid peptide hormone, was first isolated from pancreatic extracts as a peptide hormone with hyperglycemic activity. Larger molecular forms with glucagon-related immunoreactivity were subsequently identified in intestinal extracts; however, the relationship between gut-derived glucagon-like immunoreactivity (GLI) and pancreatic glucagon remained unclear for some time. Initial studies estimated the size of intestinal "enteroglucagon" as ϳ100 amino acids, prompting the designation glicentin. After the cloning of pancreatic, intestinal, and brain complementary DNAs encoding proglucagon, the structural relationship between the various glucagon-related peptides was clearly delineated. [1] [2] [3] [4] [5] [6] Pancreatic glucagon is contained within the sequence of 69 amino acid glicentin ( Figures  1 and 2 ). Glucagon together with an 8 amino acid carboxyterminal peptide comprises oxyntomodulin. 7 After a short intervening peptide, 2 glucagon-like peptides, designated GLP-1 and GLP-2, are located carboxyterminally in the proglucagon molecule separated from each other by a second intervening peptide.
Fish, reptiles, and birds may contain multiple genes for proglucagon. 8 However, only a single proglucagon gene has been identified in mammals. The nucleotide sequence of mammalian proglucagon messenger RNA (mRNA) transcripts and proglucagon gene transcription start sites appear identical in fetal and adult pancreas, intestine, and brain. 5,6,9 -11 Hence, tissue-specific posttranslational processing of proglucagon accounts for the diversity in the profile of secreted proglucagon-derived peptides (PGDPs) in the pancreas and gut (Figure 1 ). In contrast, alternative RNA splicing generates unique proglucagon mRNA transcripts in the pancreas and intestine of fish, chicken, and reptiles. 12, 13 Although the prohormone convertase (PC) enzymes that liberate PGDPs in the central nervous system have yet to be con-clusively identified, PC2 is thought to play a key role in the liberation of pancreatic glucagons, 14 -16 whereas PC1/3 is important for generation of the glucagon-like peptides in enteroendocrine cells. [17] [18] [19] [20] Enteroendocrine L cells producing GLP-1 and GLP-2 are detected throughout the length of the small and large bowel, with the majority of L cells localized to the distal ileum and colon. L cell subpopulations have been characterized on the basis of hormonal phenotype, with some cells producing principally PGDPs, or PGDPs in combination with other gut peptides such as peptide YY (PYY), cholecystokinin, or neurotensin. The distal location of the majority of PGDP-producing endocrine cells is somewhat paradoxical in view of the rapid increase in circulating PGDPs detectable within minutes of nutrient ingestion in both rodents and humans. [21] [22] [23] [24] Current concepts of L cell regulation involve the integration of humoral and neural mediators such as gastrin-releasing peptide and glucose-dependent insulinotropic polypeptide (GIP) and neural inputs in the control of intestinal PGDP secretion. Peptide administration and immunoneutralization experiments support a role for somatostatin-28 as an inhibitor of both GLP-1 and GLP-2 secretion. 25 The importance of neural signaling for secretion of PGDPs is illustrated by studies of vagal nerve interruption that result in marked attenuation of nutrientstimulated PGDP secretion in the rat. 26 Nutrients also up-regulate proglucagon mRNA transcripts in the rodent jejunum, 27 and fermentable fiber feeding or fatty acid infusion is associated with increased intestinal proglucagon gene expression in the rat intestine. 28 -31 The initial increment in levels of circulating GLP-1 and GLP-2 following meal ingestion is followed by rapid inactivation and clearance of these peptides from the circulation. Both GLP-1 and GLP-2 contain an alanine at position 2, rendering them substrates for the exopeptidase dipeptidyl peptidase IV (DP IV). Bioactive GLP-1 exists in two equipotent molecular forms (Figure 2 ), GLP-1 and GLP-1 7-36amide . 32 GLP-1 is rapidly cleaved by DP IV, 33 resulting in the generation of the largely inactive molecules GLP-1 9-36amide and GLP-1 . 34, 35 The majority of GLP-1 leaving the intestinal venous circulation has already been cleaved by DP IV expressed in capillaries surrounding gut L cells, 36 leading to an estimated half-life for intact GLP-1 of ϳ1-2 minutes in vivo. 35 GLP-2 is also inactivated by DP IV in rodents and humans [37] [38] [39] ; however, native GLP-2 exhibits a slightly longer half-life of 5-7 minutes in human subjects. 40 GLP-1 and GLP-2 are also cleared nonenzymatically, and several organs, including the kidney, have been invoked as important sites for PGDP clearance in vivo. [41] [42] [43] 
GLP-1 Actions in the Gastrointestinal Tract and Pancreas
The actions of GLP-1 are mediated by a single GLP-1 receptor widely expressed in the kidney, heart, central nervous system, gastrointestinal tract, and in the endocrine pancreas. 44 -46 The GLP-1 receptor has been localized to human chromosome 6p21 47 ; however, significant linkage to diseases such as diabetes has not yet been detected. 48 GLP-1 infusion inhibits sham feedinginduced acid secretion in normal human subjects, 49 -51 and these actions on acid secretion are dependent on both somatostatin receptor activation and intact gastric vagal innervation. 52, 53 GLP-1 receptor mRNA transcripts and GLP-1 binding have also been observed in purified rat and rabbit gastric parietal cell populations. 54, 55 In contrast, GLP-1 inhibits human gastric lipase secretion in a vagal nerve-independent manner. 56 Exogenous GLP-1 administration potently inhibits gastric emptying in rodent and human studies. 49 Intracerebroventricular (ICV) administration of GLP-1 also inhibits gastric emptying in rodents which is abolished by vagal afferent denervation, but not by cholinergic or adrenergic blockade. 57 Adrenergic blockade eliminates the inhibitory actions of GLP-1 on antral, duodenal, and jejunal motility in the rat 58 and splanchnic nerve transection abrogates the inhibitory effects of GLP-1, mediated by the vagus nerve and parasympathetic outflow, on acid secretion and gastric motility in the pig. 59 GLP-1 also inhibits small bowel motility in the rat and these actions of GLP-1 are blocked by the nitric oxide synthase inhibitor N -nitro-L-arginine in the fasted but not fed state. 60 Taken together, the antimotility and antisecretory effects of GLP-1 suggest that GLP-1 released from the distal gut represents a candidate mediator of the ileal brake phenomenon in vivo. The actions of GLP-1 on gastric emptying result in a reduced rate of nutrient transit into the small bowel, leading to decreased glycemic excursion after meal ingestion. 61, 62 The effect of exogenous GLP-1 on gastric emptying is observed with levels of plasma GLP-1 within the physiological range of endogenous plasma levels that might be achieved after meal ingestion. 63 Original descriptions of GLP-1 action focused on its role as a gut-derived incretin that stimulated glucose-dependent insulin secretion. 22,64 -66 GLP-1 acts as a physiological regulator of insulin secretion as the truncated lizard peptide exendin (9-39), a functional GLP-1 receptor antagonist, reduces insulin secretion and enhances glycemic excursion following blockade of GLP-1 action in vivo. [67] [68] [69] Similarly, mice with genetic disruption of GLP-1 receptor signaling exhibit glucose intolerance and reduced glucose-stimulated insulin secretion. 70 Although GLP-1 stimulates pancreatic somatostatin secretion and inhibits glucagon secretion, 71 GLP-1R Ϫ/Ϫ mice exhibit normal levels of glucagon in the fasting state and preserved suppression of plasma glucagon following oral glucose challenge. 72 Increasing evidence supports a role for GLP-1R signaling in the regulation of ␤-cell proliferation and islet neogenesis. GLP-1 promotes ␤-cell replication in the mouse, 73 and directly stimulates DNA synthesis in islet cell lines in vitro via a phosphatidylinositol 3-kinasedependent pathway. 74 GLP-1 also promotes development of a more differentiated ␤-cell phenotype in islet, ductal, and exocrine cells via a pdx-1-dependent pathway. [75] [76] [77] GLP-1 or the lizard GLP-1 agonist exendin-4 stimulate ␤-cell neogenesis in diabetic db/db mice in association with increased ductal pdx-1 expression, likely attributable to stimulation of pdx-1 promoter activity in both small and large pancreatic ducts in vivo. 78 Similarly, daily administration of exendin-4 to neonatal rats for 10 days after partial pancreatectomy lowered blood glucose, stimulated islet regeneration, and increased ␤-cell mass 79 and administration of GLP-1 or exendin-4 to neonatal rats treated with streptozotocin resulted in increased ␤-cell mass, which remained detectable even at 2 months of age. 80 Conversely, elimination of GLP-1 receptor signaling is associated with reduced numbers of large islets and abnormal topographical localization of islet A cells in GLP-1R Ϫ/Ϫ mice. 81 Hence, these findings have fostered considerable interest in harnessing the trophic properties of GLP-1 for the treatment of type 2 diabetes characterized by progressive ␤ cell failure.
GLP-1, Appetite, and the Central Nervous System
The finding that ICV GLP-1 administration dosedependently inhibits food intake in rats and mice, 70, [82] [83] [84] in association with experimental data demonstrating increased food intake and weight gain following chronic ICV administration of the GLP-1 receptor antagonist exendin (9-39), 85 has engendered considerable interest in the anorexic properties of GLP-1 agonists. Subsequent studies demonstrated that peripheral administration of GLP-1 or exendin-4 to rodents also reduced short-term and long-term food intake, 86 raising the possibility that therapeutic administration of GLP-1 may prevent weight gain and perhaps induce weight loss in human subjects. Although long-term human studies of GLP-1 treatment are not yet available, GLP-1 and exendin-4 clearly reduce appetite and food consumption following peripheral administration in normal or diabetic human subjects. [87] [88] [89] [90] The mechanism(s) used by GLP-1 agonists for transduction of anorectic signals remain unclear. Inhibition of gastric emptying may account for a component of the satiety experienced after GLP-1 administration. GLP-1 receptors are expressed on hypothalamic nuclei that control food intake, 82, 91, 92 and peripheral GLP-1 may exert indirect effects on CNS satiety centers through neuronal relay mechanisms. Intriguingly, both GLP-1 agonists and noxious agents such as lithium chloride or lipopolysaccharide induce a similar pattern of central c-fos activation in the CNS and an overlapping set of aversive behavioral responses in rodents in vivo. [93] [94] [95] Moreover, some aversive responses to noxious stimuli are blocked by the coadministration of the GLP-1 antagonist exendin (9-39), 96 suggesting the involvement of GLP-1R signaling pathways in the response to aversive stress. Whether GLP-1 signaling pathways are essential for physiological control of appetite and body weight remains unclear, as GLP-1R Ϫ/Ϫ mice exhibit normal food intake and weight gain 70 and are resistant to the development of obesity, even after 6 months of high-fat feeding. 97 Taken together, the inhibitory effects of GLP-1 agonists on food intake may prove to be highly useful if sustained in long-term treatment studies of human subjects with type 2 diabetes.
GLP-1 Agonists and Therapy of Type 2 Diabetes
The actions of GLP-1 including inhibition of gastric emptying, stimulation and inhibition of insulin and glucagon secretion, respectively, expansion of ␤-cell mass and reduction of food intake and weight gain, represent ideal properties for an agent designed for the treatment of type 2 diabetes. 98 Furthermore, GLP-1 actions are highly glucose-dependent, hence excess GLP-1 administration is unlikely to be associated with hypoglycemia in vivo. A principal obstacle to the long-term use of the native GLP-1 molecule in the clinic is the rapid inactivation of the peptide by the enzyme DP IV. 34, 35 As DP IV inhibition prolongs the duration of GLP-1 action, the development of DP IV inhibitors is being actively pursued as a potential strategy for the treatment of diabetes. 99 Although DP IV, also known as CD26, cleaves a large number of regulatory peptides and chemokines, 100,101 mice and rats with inactivating DP IV mutations are viable and exhibit enhanced GLP-1 action and glucose clearance, 102, 103 attesting to the essential role of this enzyme for glucoregulation in vivo.
These findings have spurred efforts toward development of DP IV-resistant GLP-1 analogues or related molecules such as lizard exendin-4 that exert longer durations of efficacy in human subjects. 90,104 -106 GLP-1 infusion normalizes 24-hour blood glucose profiles in subjects with type 2 diabetes, 89,107-109 even in patients with previous sulfonylurea failure. 110 -112 The majority of these studies have been carried out for days to weeks; hence, whether treatment with GLP-1 agonists will achieve sustained control of blood glucose in long-term studies is currently under examination. Furthermore, the current lack of oral GLP-1 agonist molecules seems likely to diminish the potential for initial widespread adoption of GLP-1 therapy as a mainstream treatment for patients with type 2 diabetes well managed on oral agents alone. Nevertheless, as many patients with type 2 diabetes develop progressive ␤-cell failure on oral agents, the potential for GLP-1 to preserve or augment ␤-cell function in such patients merits careful examination.
Glucagon-like Peptide-2
GLP-2 is a 33 amino acid peptide cosecreted with GLP-1 from enteroendocrine L cells in the small and large intestine. The biological role of GLP-2 remained obscure until 1996, when GLP-2 was shown to be a potent stimulator of mucosal epithelial proliferation in the murine small intestine. 113 Studies linking proglucagon-derived peptides to intestinal growth and adaptation were fostered by the description of a patient with a glucagonoma who presented with small intestinal mucosal hyperplasia and reduced bowel motility. 114 Tumor resection led to resolution of the small bowel villus hyperplasia. Subsequent studies in rodents correlated increased circulating levels of the PGDPs with the adaptive response to experimental intestinal injury. [115] [116] [117] [118] Furthermore, intestinal resection is associated with enhanced circulating levels of the PGDPs and increased levels of intestinal proglucagon mRNA transcripts in remnant intestinal segments. 119 -122 The correlation between intestinal injury, gut adaptation, and up-regulation of circulating PGDPs, demonstrated by Bloom et al., 118 is not restricted to rodents, as a broad variety of intestinal diseases that affect the integrity of the mucosal epithelium are associated with increased circulating levels of the PGDPs in human subjects. [123] [124] [125] [126] Additional reports describing glucagonoma patients with intestinal mucosal hyperplasia, [127] [128] [129] taken together with studies linking experimental glucagonomas in mice with small bowel growth, led to definitive identification of GLP-2 as the PGDP with significant intestinotrophic properties in vivo. 113 Although glicentin also exhibits modest intestinotrophic properties 113, 130 it is much less active as a small bowel growth factor when compared directly with GLP-2, 113,131 and a separate receptor for glicentin has not yet been identified.
Glucagon-like Peptide-2: Synthesis and Secretion
The sequence of GLP-2 is highly conserved in vertebrates with rat and mouse GLP-2 sequences differing from human GLP-2 by a single amino acid. 8 GLP-2, like GLP-1, contains an alanine at position 2 (Figure 2 ), rendering it a substrate for DP IV cleavage. Analysis of the circulating forms of GLP-2 in rats and humans demonstrates the presence of GLP-2 and the N-terminally inactivated peptide GLP-2 3-33 . 37, 39, 40, 132, 133 Consistent with the importance of DP IV for degradation of bioactive GLP-2, the wild-type GLP-2 1-33 molecule is considerably less potent than DP IV-resistant GLP-2 analogues in rat studies in vivo. 38, 134 In contrast to the comparatively shorter half-life of GLP-1, the disappearance half-life of exogenously administered GLP-2 is ϳ7 minutes in normal human subjects. 40 Furthermore, ϳ69% of GLP-2 1-33 remains intact 1 hour following subcutaneous administration of 400 g of synthetic GLP-2 in normal human subjects. 40 The clearance of GLP-2 1-33 is significantly reduced in nephrectomized rats 43 and levels of plasma GLP-2 are increased in human subjects with kidney failure, 37 in keeping with an important role for the kidney in GLP-2 clearance. 41 Radioimmunoassays that only recognize mid-molecule or carboxyterminal epitopes in the GLP-2 sequence will not distinguish between intact GLP-2 1-33 and partially degraded forms of the molecule and will yield overestimations of the amount of biologically active circulating GLP-2 1-33 . 37, 39, 40 Nutrient ingestion constitutes the principal stimulus for GLP-2 secretion. 37, 39, 40, 133 The levels of GLP-2 increase within minutes of nutrient ingestion. 37, 39, 133 In pigs, provision of at least 40% of total nutrient intake via the enteral route is required for stimulation of significant increases in circulating GLP-2 135 whereas ingestion of a donut and coffee (ϳ220 calories) is sufficient to significantly increase circulating GLP-2 in normal human subjects. 37 An intact colon in continuity with the small bowel is an important determinant of the circulating levels of GLP-2, as subjects with short bowel syndrome without a colon in continuity exhibit reduced circulating levels of meal-stimulated GLP-2. 136 In contrast, patients with less than 140 cm of remnant small bowel but with an intact continuous colon had elevated levels of GLP-2. 137 Circulating levels of GLP-2 were increased in patients with active Crohn's disease or ulcerative colitis, in association with a relative increase in the ratio of intact GLP-2 vs the N-terminally cleaved GLP-2 , and a decrease in levels of plasma DP IV activity. 132 Intriguingly, rodents with diabetes develop small bowel villous hyperplasia that may be explained in part by increased levels of circulating GLP-2 that correlate with the extent of small bowel growth. 138, 139 Treatment of diabetic rats with insulin lowers levels of circulating GLP-2 and reverses the intestinal mucosal hyperplasia. 138 
GLP-2 Action in the Gastrointestinal Tract
The principal histological finding in the rodent gut after repeated GLP-2 administration is mucosal growth in the small bowel due to stimulation of cell proliferation in the crypt compartment and inhibition of enterocyte apoptosis, 113,131,140 -142 principally evident histologically as elongation of the villous epithelium ( Figure 3) . A modest expansion of the crypt compartment may be seen in some, but not all, studies after GLP-2 administration. The GLP-2-treated murine small bowel exhibits normal levels of digestive enzymes and normal to enhanced nutrient absorption following nutrient tolerance testing. 143 Intravenous GLP-2 infusion also significantly increased the absorption of 14 C-galactose and 14 C-glycine from perfused intestinal segments of rats following 14 days of intravenous human GLP-2 infusion. 144 Ultrastructural analysis of the GLP-2-treated murine small bowel reveals longer and narrower enterocytes with longer microvilli. 145 Remarkably, GLP-2 enhances epithelial barrier function in the murine small bowel via reduction of tissue conductance and macromolecule flux, effects noted within 4 hours of a single GLP-2 injection in vivo. 145 Although the small bowel is significantly more sensitive to the stimulatory effects of GLP-2 compared with the colon, 131, 140, 146 treatment with higher doses of GLP-2 or more potent GLP-2 agonists also produces modest increments in large bowel mucosal thickness. 131, 134 The most rapid actions of GLP-2 include enhancement of mucosal hexose transport, 147, 148 inhibition of gastric acid secretion, 149 and reduction of gastric motility. 150 In contrast to the actions of GLP-1, GLP-2 has no effect on regulation of glucose homeostasis in vivo. 143, 150 The minimal and optimal GLP-2 administration regimen for induction of bowel growth remains unclear; however, a single injection of GLP-2 every other day over a 10-day treatment period is sufficient to promote significant increases in small bowel growth in mice. 140 
GLP-2 and Intestinal Injury
The mucosal atrophy observed in the intestine of parenterally fed rodents may be attributable in part to reduced circulating levels of GLP-2 in the absence of periodic nutrient stimulation of GLP-2 secretion. Intravenous infusion of GLP-2 together with parenteral nutrition prevented mucosal hypoplasia in the small bowel, but not in the large bowel of fasted rats. 131, 151 The trophic effects of exogenous GLP-2 on the rat small bowel mucosa were also preserved in parenterally fed tumor-bearing rats. 152 Furthermore, GLP-2 treatment increased small bowel mass and DNA content but had no effect on the colon or on tumor growth. 152 As the circulating levels of PGDPs and GLP-2 are increased in rats after small bowel resection, 141 the effects of GLP-2 administration on small bowel adaptation have been examined in a rat model of jejunoileal resection. Rats treated for 21 days with twice daily injections of a GLP-2 analogue exhibited no differences in food intake, body weight, or small bowel length, but significant increases in mucosal weights were observed in the jejunum and ileum of GLP-2-treated rats following resection. 153 GLP-2 treatment also increased crypt plus villus height, jejunal sucrase activity, and fractional urinary xylose excretion, the latter parameter consistent with a GLP-2-mediated improvement in intestinal sugar absorption. 153 The reparative and protective properties of GLP-2 have been assessed in the setting of experimental intestinal inflammation in the small and large bowel. Mice treated with the nonsteroidal agent indomethacin develop small bowel enteritis associated with significant mortality evident between 48 -72 hours after indomethacin administration. 154 Treatment with a DP IV-resistant GLP-2 analogue, h[Gly2]-GLP-2, either before, concomitant with, or following indomethacin significantly reduced mortality and decreased mucosal injury. 154 The protective effects of h[Gly 2 ]-GLP-2 were associated with significantly increased crypt cell proliferation and decreased crypt compartment apoptosis in the small bowel epithelium of indomethacin-treated mice. A marked reduction in myeloperoxidase activity was detected in the jejunum and ileum, in association with reduced levels of TNF-␣, interleukin-2, interferon-␥, and interleukin-10 in h[Gly 2 ]-GLP-2-treated mice. 154 The reduced mortality may potentially be explained by a significant reduction in the number of septic animals exhibiting bacterial culture positivity in viscera and blood following h[Gly 2 ]-GLP-2 administration. Consistent with these findings, h[Gly2]-GLP-2 reduced intestinal permeability and the extent of bacterial translocation in rats with experimental pancreatitis. 155 The therapeutic effects of GLP-2 have also been examined in HLA-B27 rats after development of spontaneous small bowel inflammation. A 14-day infusion of GLP-2, 50 g ⅐ kg ⅐ day, reduced mucosal damage scores in the small and large intestine, with a marked reduction in colonic expression of TNF-␣ and interferon-␥ mRNA transcripts. 156 Administration of a GLP-2 analogue preserved mucosal mass and reduced mortality, with accelerated recovery of mucosal absorption of galactose and glycine after ischemia/reperfusion injury in rats. 157, 158 Reduced intestinal injury following GLP-2 treatment has also been observed in mice with dextran sulfateinduced colitis. Concomitant administration of subcutaneous h[Gly 2 ]-GLP-2 and oral dextran sulfate (DS) for 10 days resulted in markedly reduced colonic damage and decreased weight loss in CD1 and BALB/C mice. 159 h[Gly 2 ]-GLP-2 preserved large bowel length, decreased intestinal damage scores, reduced interleukin-1 expression, and stimulated colonic mucosal repair via enhanced crypt cell proliferation in mice with DS-colitis. 159 The observations that GLP-2 treatment reduced intestinal apoptosis 154 prompted assessment of the cytoprotective effects of GLP-2 administration in the setting of chemotherapy-induced intestinal mucositis. Rats treated with a GLP-2 analogue and 5Ј-fluorouracil exhibited reduced intestinal injury compared with rats treated with 5Ј-fluorouracil alone. 160 Pretreatment of mice with h[Gly 2 ]-GLP-2 before administration of the topoisomerase inhibitor irinotecan significantly reduced bacterial infection, intestinal damage, and mortality. 161 Histological and biochemical analyses revealed significant reductions in crypt compartment apoptosis and reduced intestinal caspase-8 activation following h[Gly 2 ]-GLP-2-treatment, compared with mice receiving irinotecan alone. 161 h[Gly 2 ]-GLP-2 also reduced mortality after 5-fluorouracil treatment of BDF1 mice, and repeated cyclical administration of both h[Gly 2 ]-GLP-2 and irinotecan resulted in significantly decreased mortality in groups of BALB/C mice implanted with subcutaneous CT-26 colon carcinomas, compared with identical groups of tumor-bearing mice treated with irinotecan alone. 161 The antiapoptotic actions of GLP-2 have also been observed in premature parenterally fed pigs. Intravenous infusion of GLP-2 for 6 days reduced protein degradation and significantly decreased the rate of apoptosis in the jejunum of premature pigs. 142 Taken together, exogenous GLP-2 administration clearly exerts protective and regenerative actions in the small and large bowel in a diverse number of animal models of experimental epithelial injury.
Identifying Mechanisms Mediating GLP-2 Action
GLP-2 exerts its actions through a recently identified G protein-coupled receptor isolated from hypothalamic and intestinal cDNA libraries. The GLP-2 receptor (GLP-2R) is comprised of 550 amino acids and was localized to human chromosome 17p13.3. 162 The GLP-2R is expressed in a tissue-specific manner in the stomach, small and large intestine, central nervous system, and lung. [162] [163] [164] GLP-2R expression in the human gut epithelium has been localized to subsets of enteroendocrine cells in the stomach, and both small and large intestine. 163 Although the majority of enteroendocrine cells do not express the GLP-2R, all GLP-2R-immunoreactive cells identified to date express one or more gut endocrine markers, including GIP, PYY, serotonin, chromogranin, and GLP-1. 163 In contrast, the GLP-2R has been localized to enteric neurons in the murine gastrointestinal tract. 165 These findings imply a model for GLP-2 action whereby GLP-2 released from enteroendocrine L cells acts on adjacent and distant gut endocrine cells or neurons to stimulate the release of downstream mediators of GLP-2 action (Figure 4 ).
GLP-2R signaling
has not yet been examined in cells that express an endogenous GLP-2R. GLP-2 activates an adenosine 3Ј,5Ј-cyclic monophosphate (cAMP)-dependent signaling pathway in fibroblasts transfected with the rat or human GLP-2R. 162, 166 In contrast, GLP-2 did not stimulate a significant increase in intracellular calcium accumulation and only pharmacological concentrations (100 nmol-10 mol) of GLP-2 increased cell proliferation in quiescent BHK-GLP-2R and Caco-2 cells. 166, 167 Activation of GLP-2R signaling in heterologous transfected cells inhibits apoptosis induced by cycloheximide or irinotecan, in association with reduced caspase activation, decreased mitochondrial cytochrome C release, and decreased cleavage of downstream effector enzymes such as poly ADP ribose polymerase. 161, 168 Hence, GLP-2 promotes cell survival via both direct and indirect actions in vitro and in vivo.
GLP-2 and Treatment of Human Intestinal Disease
Although GLP-2 exerts beneficial effects in experimental models of intestinal injury, experience with GLP-2 in the setting of human disease is limited. Treatment of 8 patients with short bowel syndrome and energy malabsorption with twice daily subcutaneous injections of native human GLP-2 for 35 days resulted in modest but statistically significant improvements in nutrient absorption as assessed by metabolic balance studies carried out before and after completion of GLP-2 therapy. 169 GLP-2 improved intestinal energy absorption, diminished stomal energy excretion, increased body weight and lean body mass, decreased fat mass, and enhanced urinary creatinine excretion, in association with reduced gastric emptying but normal small bowel transit times. 169 Evidence for increased growth of the small bowel mucosa was detected in biopsy specimens from 5 of 6 subjects. Mean fasting plasma levels of circulating GLP-2 increased from 11 Ϯ 5 to 719 Ϯ 281 pmol, 30 minutes after subcutaneous injection of 400 g of GLP-2. Compliance during the study was good, with 6 of 8 patients receiving all 70 subcutaneous injections, and 2 patients missed a single injection. There was no significant change in a broad panel of biochemical and hematological parameters assessed before and after GLP-2 treatment. 169 Similarly, positive results including increased wet weight absorption, decreased fecal wet weight and energy excretion, increased body weight, and enhanced fat absorption have been reported in a preliminary analysis of human short bowel patients treated with ALX-0600, a degradation-resistant GLP-2 analogue.
Glucagon-like Peptides: Future Research Directions
The original finding that GLP-1 functions as an incretin to increase insulin secretion has been followed by the delineation of multiple nonincretin actions of GLP-1 on gastric emptying, small bowel motility, glucagon secretion, and islet ␤-cell proliferation. The possibility that GLP-1 administration may also be associated with islet regeneration in human subjects with type 2 diabetes has engendered considerable interest in the development of GLP-1 analogues suitable for long-term diabetes treatment. Although GLP-1 decreases appetite and prevents weight gain in short term studies, its potential efficacy in the prevention of weight gain or induction of weight loss in human subjects chronically treated with GLP-1 analogues remains unknown. Intriguingly, the glucose-dependent actions of GLP-1 on the islet ␤ cell have recently been extended by studies demonstrating that GLP-1 receptor signaling forms an essential component of the hepatoportal glucose sensor in mice. 170 As GLP-1 receptors have been localized to glucose-sensitive neurons in regions of the hypothalamus, 92 future studies of the potential role of GLP-1 receptor signaling in the CNS response to hypoglycemic stress appear warranted. Most importantly, whether GLP-1 analogues will exhibit sustained efficacy and safety in the prolonged treatment of human subjects with type 2 diabetes requires additional investigation.
The results of preclinical studies have suggested that GLP-2 exerts both cytoprotective and regenerative effects in the small and large intestine. Nevertheless, defining the physiological role(s) of GLP-2 in the intestinal epithelium has proved problematic because of the lack of GLP-2 antagonists and the absence of naturally occurring or genetic models of GLP-2 deficiency. Although GLP-2 and its receptor are expressed and functional in the fetal and neonatal gut epithelium, 142, 171 the putative role of GLP-2 in gut development or in the neonatal to adult transition to a fully functional absorptive intestinal epithelium remains unclear. Similarly, although ICV administration of large amounts of GLP-2 inhibits food intake in mice and rats, 164, 172 whether GLP-2 receptor signaling is essential for physiological appetite control or whether GLP-2 subserves distinct, as yet unidentified actions in the brain unrelated to nutrient intake, requires further study. An important area requiring additional analysis is the identification of mechanisms activated by GLP-2R signaling in enteroendocrine cells and neurons and the nature of the humoral, neural, and paracrine mediators released in response to GLP-2R signaling.
Although the GLP-2R is expressed in subsets of human enteroendocrine cells and neurons, GLP-2R localization has not yet been examined in the setting of intestinal disease. Furthermore, whether GLP-2 will prove to be therapeutically useful in human subjects with inflammatory bowel disease, or in the setting of chemotherapy administration, will require careful assessment in clinical trials. Moreover, the only patients treated to date with exogenous GLP-2 have lacked a colon in continuity 169 ; hence, the therapeutic efficacy of GLP-2 in patients with an intact colon merits examination. Furthermore, the combination of enhanced proliferation and decreased apoptotic activity in the rodent small bowel observed following GLP-2 treatment suggests that intermittent surveillance of the colon in human subjects receiving chronic GLP-2 administration appears prudent. Taken together, the unique biological actions of the PGDPs in the absorption and disposal of ingested energy, taken together with the preliminary results to date from human studies of GLP-1 and GLP-2, suggests that these peptides may soon prove useful in the treatment of specific subsets of patients with diabetes and intestinal disease.
